Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





GC Labs Highlight Its “Smart Lab” Concept at MEDLAB Middle East 2022

By LabMedica International staff writers
Posted on 24 Jan 2022

GC Labs (Yongin, South Korea) participated in the 2022 edition of MEDLAB Middle East held at the Dubai World Trade Centre (DWTC) from January 24 to 27 where it offered a ‘smart experience’ for visitors to learn more about the diagnostic services offered by the company. More...

At the event, GC Labs highlighted its “smart lab” concept that provides an automated test system to improve speed and efficiency of tests, allowing the company to report results in just a day or two. The increase in demand for genetics and infectious disease tests in the region has prompted GC Labs to plan further expansion in the Middle East. Currently offering their services in Saudi Arabia and the UAE, the company is in talks with regional partners to expand their services to more countries in the Middle East. More than 800 employees at GC Labs offer over 5,000 tests and test combinations, ranging from routine tests to highly esoteric molecular and genetic assays.

GC Labs hosted its seminar on ‘Public-Private Partnership in Global Health: bringing the best of both worlds to improve testing’ on January 25 at the Bubble Lounge in Medlab. The seminar had an impressive line-up of speakers with globally renowned specialists including Lelio Marmora, former CEO in Unitaid; Michel Kazatchkine, former executive director the Global Fund to Fight AIDS, TB and Malaria; Dr Eskild Petersen, MD, Editor-in-chief of IJID Regions, an official journal of the International Society for Infectious Diseases (ISID); Dr Amina Al-Jardani, Director of Central Public Health Laboratories (CPHL), Directorate General for Disease Surveillance and Control, Ministry of Health, Oman; and Lee. The seminar was an interactive session with an opportunity for attendees to ask questions.

“The Middle East is an important market for us, and participating in MEDLAB will help us to share our best practices in clinical diagnostics with the regional health community. Over the past two decades, the world has achieved important success in the fight against pandemics like COVID-19 and in mobilizing global response against HIV-Aids, TB, Malaria and other infectious diseases,” said Eun-Hee Lee, President at GC Labs. “Medical laboratories play a key role in this fight by providing high quality diagnostic testing and by working in partnership with the health authorities. To highlight the importance of private and public partnership in the fight against infectious diseases and pandemics, we are organizing a seminar during MEDLAB to bring together international experts to share their own experiences and expertise, focus on lessons learned, and discuss how to best manage public and private partnerships to successfully fight against pandemics and infectious diseases in the future.”

Related Links:
GC Labs 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.